MOXIFLOXACIN HYDROCHLORIDE

Post-LOE

moxifloxacin hydrochloride

Teva

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Feb 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MOXIFLOXACIN HYDROCHLORIDE (moxifloxacin hydrochloride) by Teva is anti-infective drugs [see ] . Approved for bacterial conjunctivitis caused by susceptible strains of the following organisms: corynebacterium species*, micrococcus luteus*, staphylococcus aureus and 10 more indications. First approved in 2021.

Drug data last refreshed 18h ago

Mechanism of Action

anti-infective drugs [see ] .

Indications (13)

bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*Micrococcus luteus*

Worked on MOXIFLOXACIN HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MOXIFLOXACIN HYDROCHLORIDE

Mechanism of Action

Indications (13)

Clinical Trials (1)